Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Consequences Of Aneuploidy As Cause, Not Effect, Of The Cancer Genome

This article was originally published in Start Up

Executive Summary

Geneticists from Harvard Medical School have now shown that aneuploidy, or the occurrence of an extra or missing number of chromosomes within a cell, actually drives tumors, rather than being a byproduct of tumor formation, giving support to the development of aneuploidy-directed cancer treatment strategies.

You may also be interested in...

Genetic Approaches Look Beyond Oncogenes For Cancer Therapy Targets

A half decade of large-scale cancer genome sequencing has identified only one new and relatively common druggable oncogene target. But the genes that cause out-of-control proliferation also create problems for the cancer cells, which may then need to hijack normal cellular functions to help them survive. A research team used genetic screening to find such a dependency and showed that inhibiting the process could improve treatment.

Personalizing Standard Chemotherapy And A Potential New Combination Treatment Strategy

A recent report shows that some cancer cells may be more sensitive to chemotherapy because their mitochondria are primed to undergo programmed cell death. An assay that identifies the start of the process could help optimize the use of traditional chemo. And novel agents not potent enough to be used against tumors on their own could selectively prime tumors in this way as part of combination therapy.

Science Matters: Targeting Heme Trafficking In A Variety Of Diseases

A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts